ABOzymes Biomedical effectively doubles the supply of universal donor blood (type-O) to save lives. In emergency situations when there isn’t time to cross-match the patient’s blood type, doctors have to use universal donor blood to save their life. Unfortunately, this blood type is always in short supply. ABOzymes Biomedical’s technology makes all blood O-type, so any blood can be used for any patient, regardless of their respective blood types.
These products will ensure the safe and timely supply of type-O blood. In the next five years, ABOzymes Biomedical intends to secure product licences in the US and Canadian blood markets.
Past experience, future success
ABOzymes Biomedical built their business on strong technologies, but successful ventures must combine technology with experienced management. The four-person founding team are veteran start-up builders. They’ve expanded their networks and assembled an experienced management team that has established sound corporate governance and product development principles, ensuring ABOzymes Biomedical is highly productive.
Where the Competition fits in
The extensive network and public support, the New Ventures BC Competition, presented by Innovate BC offers winners made ABOzymes Biomedical team eager to apply to the 20th Annual Competition. ABOzymes Biomedical hopes to grow its business, launch their product, and secure a deeper understanding of corporate and product development through the competition.
Dr. Peter Rahfeld | Co-founder and Co-inventor
Peter is a co-founder of ABOzymes Biomedical and co-inventor of our blood type converting technology. Peter got his doctoral degree (Dr. rer. nat.) from the Max- PlancK -Institute in Germany 2015 and has since worked on the discovery of novel carbohydrate active enzymes (CAZymes) with applications in human health.
Spence Macdonald | Co-founder
Since beginning his Ph.D. work at the University of British Columbia, Spence has been focusing on developing translational research to solve real world problems. Thanks in large part to ECOSCOPE, an entrepreneurial training program at UBC, Spence was given the opportunity to explore the bio-tech start-up landscape and has given him the experience to help ABOzymes reach its potential.
Haisle Moon | Co-founder
Haisle is one of the co-founders of ABOzymes Biomedical and is currently studying red blood cell modifications and blood immunology as her Ph.D. project at the University of British Columbia.
Dr. Geoffrey Houlton | Co-founder
Geoff is a retired physician who worked in product development in the UK and Canadian pharmaceutical industry. He also worked in venture capital before becoming a healthcare financial analyst. In 2012 he moved to Vancouver to take the helm of Heart Force Medical.
ABOzymes Biomedical is located in Vancouver, B.C.
Click here to find out more about ABOzymes Biomedical and the other Top 10 Finalists of the New Ventures BC Competition, presented by Innovate BC.